通过流式细胞术,合成异常肥大细胞颗粒成功模拟了肿瘤肥大细胞。

IF 2.3 3区 医学 Q3 MEDICAL LABORATORY TECHNOLOGY Cytometry Part B: Clinical Cytometry Pub Date : 2024-05-30 DOI:10.1002/cyto.b.22183
Patricia M Davis, Eugene Ravkov, Martina de Geus, Zach Clauss, John Lee, Anh Tuan Nguyen, Marsha Hartmann, Jeffrey Kim, Tracy I George, Leo Lin, David P Ng
{"title":"通过流式细胞术,合成异常肥大细胞颗粒成功模拟了肿瘤肥大细胞。","authors":"Patricia M Davis, Eugene Ravkov, Martina de Geus, Zach Clauss, John Lee, Anh Tuan Nguyen, Marsha Hartmann, Jeffrey Kim, Tracy I George, Leo Lin, David P Ng","doi":"10.1002/cyto.b.22183","DOIUrl":null,"url":null,"abstract":"<p><p>Clinical flow cytometry laboratories require quality control materials for assay development, validation, and performance monitoring, including new reagent lot qualification. However, finding suitable controls for populations with uncommonly expressed antigens or for rare populations, such as mast cells, can be difficult. To that end, we evaluated synthetic abnormal mast cell particles (SAMCP), developed together with, and manufactured by, Slingshot Biosciences. The SAMCP's were designed to phenotypically mimic abnormal neoplastic mast cells: they were customized to have the same light scatter and autofluorescence properties of mast cells, along with surface antigen levels of CD45, CD33, CD117, CD2, CD25, and CD30 consistent with that seen in mast cell disease. We evaluated several performance characteristics of these particles using ARUP's high sensitivity clinical mast cell assay, including limit of detection, off-target activity and FMO controls, precision, scatter properties of the particles utilizing several different cytometer platforms, and particle antigen stability. The phenotype of the SAMCP mimicked abnormal mast cells, and they could be distinguished from normal native mast cells. FMO controls demonstrated specificity of each of the markers, and no off-target binding was detected. The limit of detection of the particles spiked into normal bone marrow was found to be ≤0.003% in a limiting dilution assay. The mast cell particles were found to perform similarly on Becton Dickinson Lyric, Cytek Aurora, and Beckman Coulter Navios and CytoFLEX platforms. Within run and between run precision were less than 10% CV. SAMCP were stable up to 13 days with minimal loss of antigen fluorescence intensity. The SAMCP's were able to successfully mimic neoplastic mast cells based on the results of our high sensitivity mast cell flow cytometry panel. These synthetic cell particles represent an exciting and innovative technology, which can fulfill vital needs in clinical flow cytometry such as serving as standardized control materials for assay development and performance monitoring.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthetic abnormal mast cell particles successfully mimic neoplastic mast cells by flow cytometry.\",\"authors\":\"Patricia M Davis, Eugene Ravkov, Martina de Geus, Zach Clauss, John Lee, Anh Tuan Nguyen, Marsha Hartmann, Jeffrey Kim, Tracy I George, Leo Lin, David P Ng\",\"doi\":\"10.1002/cyto.b.22183\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Clinical flow cytometry laboratories require quality control materials for assay development, validation, and performance monitoring, including new reagent lot qualification. However, finding suitable controls for populations with uncommonly expressed antigens or for rare populations, such as mast cells, can be difficult. To that end, we evaluated synthetic abnormal mast cell particles (SAMCP), developed together with, and manufactured by, Slingshot Biosciences. The SAMCP's were designed to phenotypically mimic abnormal neoplastic mast cells: they were customized to have the same light scatter and autofluorescence properties of mast cells, along with surface antigen levels of CD45, CD33, CD117, CD2, CD25, and CD30 consistent with that seen in mast cell disease. We evaluated several performance characteristics of these particles using ARUP's high sensitivity clinical mast cell assay, including limit of detection, off-target activity and FMO controls, precision, scatter properties of the particles utilizing several different cytometer platforms, and particle antigen stability. The phenotype of the SAMCP mimicked abnormal mast cells, and they could be distinguished from normal native mast cells. FMO controls demonstrated specificity of each of the markers, and no off-target binding was detected. The limit of detection of the particles spiked into normal bone marrow was found to be ≤0.003% in a limiting dilution assay. The mast cell particles were found to perform similarly on Becton Dickinson Lyric, Cytek Aurora, and Beckman Coulter Navios and CytoFLEX platforms. Within run and between run precision were less than 10% CV. SAMCP were stable up to 13 days with minimal loss of antigen fluorescence intensity. The SAMCP's were able to successfully mimic neoplastic mast cells based on the results of our high sensitivity mast cell flow cytometry panel. These synthetic cell particles represent an exciting and innovative technology, which can fulfill vital needs in clinical flow cytometry such as serving as standardized control materials for assay development and performance monitoring.</p>\",\"PeriodicalId\":10883,\"journal\":{\"name\":\"Cytometry Part B: Clinical Cytometry\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cytometry Part B: Clinical Cytometry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/cyto.b.22183\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytometry Part B: Clinical Cytometry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cyto.b.22183","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

临床流式细胞仪实验室需要质控材料来进行检测开发、验证和性能监控,包括新试剂批次鉴定。然而,要为不常表达抗原的群体或肥大细胞等稀有群体找到合适的对照物却很困难。为此,我们评估了与 Slingshot 生物科学公司合作开发并由其生产的合成异常肥大细胞颗粒 (SAMCP)。SAMCP 的设计旨在表型上模拟异常肿瘤肥大细胞:它们具有与肥大细胞相同的光散射和自发荧光特性,以及与肥大细胞疾病中常见的 CD45、CD33、CD117、CD2、CD25 和 CD30 表面抗原水平一致。我们使用 ARUP 的高灵敏度临床肥大细胞检测法评估了这些颗粒的几个性能特征,包括检测限、脱靶活性和 FMO 控制、精确度、使用几种不同细胞计数器平台的颗粒散射特性以及颗粒抗原稳定性。SAMCP 的表型模拟了异常肥大细胞,可以与正常的原生肥大细胞区分开来。FMO 对照证明了每种标记物的特异性,没有检测到脱靶结合。在极限稀释试验中发现,添加到正常骨髓中的颗粒的检测限≤0.003%。肥大细胞颗粒在 Becton Dickinson Lyric、Cytek Aurora 和 Beckman Coulter Navios 及 CytoFLEX 平台上的表现相似。运行内和运行间的精度均小于 10%CV。SAMCP 的稳定性长达 13 天,抗原荧光强度损失极小。根据我们的高灵敏度肥大细胞流式细胞仪检测结果,SAMCP 能够成功模拟肿瘤肥大细胞。这些合成细胞颗粒代表了一种令人兴奋的创新技术,可以满足临床流式细胞仪的重要需求,如作为检测开发和性能监测的标准化对照材料。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Synthetic abnormal mast cell particles successfully mimic neoplastic mast cells by flow cytometry.

Clinical flow cytometry laboratories require quality control materials for assay development, validation, and performance monitoring, including new reagent lot qualification. However, finding suitable controls for populations with uncommonly expressed antigens or for rare populations, such as mast cells, can be difficult. To that end, we evaluated synthetic abnormal mast cell particles (SAMCP), developed together with, and manufactured by, Slingshot Biosciences. The SAMCP's were designed to phenotypically mimic abnormal neoplastic mast cells: they were customized to have the same light scatter and autofluorescence properties of mast cells, along with surface antigen levels of CD45, CD33, CD117, CD2, CD25, and CD30 consistent with that seen in mast cell disease. We evaluated several performance characteristics of these particles using ARUP's high sensitivity clinical mast cell assay, including limit of detection, off-target activity and FMO controls, precision, scatter properties of the particles utilizing several different cytometer platforms, and particle antigen stability. The phenotype of the SAMCP mimicked abnormal mast cells, and they could be distinguished from normal native mast cells. FMO controls demonstrated specificity of each of the markers, and no off-target binding was detected. The limit of detection of the particles spiked into normal bone marrow was found to be ≤0.003% in a limiting dilution assay. The mast cell particles were found to perform similarly on Becton Dickinson Lyric, Cytek Aurora, and Beckman Coulter Navios and CytoFLEX platforms. Within run and between run precision were less than 10% CV. SAMCP were stable up to 13 days with minimal loss of antigen fluorescence intensity. The SAMCP's were able to successfully mimic neoplastic mast cells based on the results of our high sensitivity mast cell flow cytometry panel. These synthetic cell particles represent an exciting and innovative technology, which can fulfill vital needs in clinical flow cytometry such as serving as standardized control materials for assay development and performance monitoring.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.80
自引率
32.40%
发文量
51
审稿时长
>12 weeks
期刊介绍: Cytometry Part B: Clinical Cytometry features original research reports, in-depth reviews and special issues that directly relate to and palpably impact clinical flow, mass and image-based cytometry. These may include clinical and translational investigations important in the diagnostic, prognostic and therapeutic management of patients. Thus, we welcome research papers from various disciplines related [but not limited to] hematopathologists, hematologists, immunologists and cell biologists with clinically relevant and innovative studies investigating individual-cell analytics and/or separations. In addition to the types of papers indicated above, we also welcome Letters to the Editor, describing case reports or important medical or technical topics relevant to our readership without the length and depth of a full original report.
期刊最新文献
Prospective feasibility of a minimal BH3 profiling assay in acute myeloid leukemia. PICALM::MLLT10 fusion gene positive acute myeloid leukemia with PHF6 mutation and presented with CD7 positive immunophenotype. SingletSeeker: an unsupervised clustering approach for automated singlet discrimination in cytometry. ClearLLab 10C reagents panel can be applied to analyze paucicellular samples by flow cytometry. Improved identification of clinically relevant Acute Leukemia subtypes using standardized EuroFlow panels versus non-standardized approach.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1